We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$17.1M
Cap. Flow %
2.91%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Technology 6.31%
3 Industrials 2.63%
4 Communication Services 2.28%
5 Financials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$43.5M 7.39%
5,566
-2,434
-30% -$175K
CELG
2
DELISTED
Celgene Corp
CELG
$32.5M 5.52%
250,000
– –
BIIB icon
3
Biogen
BIIB
$30B
$24.4M 4.15%
90,000
+15,000
+20% +$3.97M
MRK icon
4
Merck
MRK
$322B
$20.5M 3.48%
335,360
+26,200
+8% +$1.59M
GSK icon
5
GSK
GSK
$104B
$19.4M 3.3%
+360,000
New +$19.2M
QQQ icon
6
PUT
Invesco QQQ Trust
QQQ
$453B
$17.2M 2.92%
+1,200
New +$165K
GILD icon
7
Gilead Sciences
GILD
$162B
$16.3M 2.77%
+230,000
New +$15.3M
NVS icon
8
Novartis
NVS
$297B
$16M 2.71%
223,200
-61,380
-22% -$4.35M
BIIB icon
9
CALL
Biogen
BIIB
$30B
$14.5M 2.46%
+500
New +$132K
BMY icon
10
Bristol-Myers Squibb
BMY
$133B
$13.8M 2.35%
248,000
+98,000
+65% +$5.33M
PFE icon
11
Pfizer
PFE
$143B
$13.1M 2.23%
411,060
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.57B
$12.9M 2.19%
383,047
-100,000
-21% -$3.26M
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$12.2M 2.07%
+100,000
New +$11.6M
SHPG
14
DELISTED
Shire pic
SHPG
$11.3M 1.92%
68,500
-146,039
-68% -$25.5M
ITRN icon
15
Ituran Location and Control
ITRN
$1.09B
$9.53M 1.62%
304,421
+23,065
+8% +$726K
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$8.71M 1.48%
+93,000
New +$5.69M
TSRO
17
DELISTED
TESARO, Inc.
TSRO
$7.69M 1.31%
+55,000
New +$7.96M
ORBK
18
DELISTED
Orbotech Ltd
ORBK
$6.97M 1.18%
213,740
+56,644
+36% +$1.92M
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.6B
$6.81M 1.16%
+75,000
New +$6.82M
CELG
20
CALL
DELISTED
Celgene Corp
CELG
$6.77M 1.15%
500
-700
-58% -$85.8K
NICE icon
21
Nice
NICE
$5.79B
$6.7M 1.14%
85,052
+21,532
+34% +$1.59M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.59M 1.12%
62,921
+12,921
+26% +$1.39M
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
$5.86M 1%
700,000
– –
VTRS icon
24
CALL
Viatris
VTRS
$20.4B
$5.85M 0.99%
+1,500
New +$57.6K
PVLA
25
Palvella Therapeutics
PVLA
$1.99B
$5.57M 0.95%
13,750
+1,250
+10% +$365K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management's Q2 2017 filing shows 41 new, 30 increased, 20 reduced and 25 closed positions. Its largest new stake was GSK: 360,000 shares worth $19.4M. The largest sale was Shire pic, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.